$BSX<\/span><\/a>), though rumors have swirled about that Bard, Endo and more may be seeking a settlement. (Johnson & Johnson was not part of those rumors.)<\/p>\r\nThe FDA is also sifting through safety data from 31 vaginal mesh-implant manufacturers and may reclassify them as Class III–or riskier–devices moving ahead.<\/p>\r\n
J&J’s first trial in the case begins Feb 10 in West Virginia, Bloomberg<\/em> noted, revolving around claims that the TVT Retropublic device, which helps support a woman’s internal organs, injured patients after eroding and shrinking.<\/p>\r\n——————————————————-
About Mark Hollmer<\/p>\r\n
Mark Hollmer<\/a> is a veteran life sciences journalist. Before joining FierceMarkets<\/a>, he was a staff writer for “The Gray Sheet,” an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State’s life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school’s life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region’s multiple museums, great restaurants and excellent cultural scene<\/p>\r\n\r\n\r\n\r\n<\/span>\r\n\r\n\r\n\r\n